Paradoxical IBD associated with IL-17 inhibitors typically manifests weeks to months after treatment initiation, with a reported latency ranging from 1 week to 2 years, and a median onset time around 3 months (8). This evidence concerns the gene IL17A and inflammatory bowel disease.